• About
    • About Us
    • Leadership
  • Investors
    • Overview
    • Press Releases
    • Governance
    • SEC Filings
    • Stock Info
    • Email Alerts
  • Contact

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

by B2i | Mar 15, 2023 | Press Releases

ROCKVILLE, Md., March 15, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

by B2i | Mar 9, 2023 | Press Releases

ROCKVILLE, Md., March 9, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

by B2i | Feb 23, 2023 | Press Releases

ROCKVILLE, Md., Feb. 23, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

by B2i | Jan 26, 2023 | Press Releases

ROCKVILLE, Md., Jan. 26, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

by B2i | Jan 17, 2023 | Press Releases

ROCKVILLE, Md., Jan. 17, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

by B2i | Jan 12, 2023 | Press Releases

ROCKVILLE, Md., Jan. 12, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
« Older Entries
Next Entries »

Recent Posts

  • Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
  • United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation
  • Shuttle Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner
  • RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
  • Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Recent Comments

No comments to show.

Contact

Shuttle Pharmaceuticals
401 Professional Drive
Suite 260
Gaithersburg, MD 20879

info@shuttlepharma.com

  • Follow
  • Follow
Sign up for Alerts

Site Links

  • Home
  • Investors
  • Privacy Policy
  • Contact

Our Company

  • About us
  • Leadership
© Copyright 2026 Shuttle Pharmaceuticals - All rights reserved
We use cookies to monitor and analyze how our site is used. By using our site, you agree to our use of cookies.